How Real-World Data Is Shaping the Future of Dengue Vaccination

• Three active investigations in 2026 have linked moringa supplement powders to a multistate Salmonella outbreak. • The outbreak has affected over 119 people across 36 different states, leading to recalls of multiple supplement brands.

• The Bundibugyo virus, a rare orthoebolavirus, remains a significant public health threat due to its ability to cause severe epidemic disease with high mortality rates. • While advances in supportive care have improved patient outcomes, there are currently no licensed vaccines or approved therapeutics specifically designed for the Bundibugyo virus.

• The CDC reports that drug overdose deaths decreased by 13.2% over the most recent 12-month period. • Experts warn this progress is fragile due to the emergence of new synthetic drugs and the use of medetomidine.

• The FDA has placed psilocybin and an MDMA-like drug on an accelerated 1-to-2 month approval track, potentially making psilocybin the first FDA-approved psychedelic therapy. • This fast-track process follows a Trump executive order and the use of priority review vouchers, with full approval possible by late 2026.

• A Salmonella outbreak linked to moringa leaf supplements has expanded to 119 reported cases across 36 U.S. states as of May 2026. • Health officials have issued warnings and multiple brands have recalled affected products to prevent further infections.

• On June 22, the FDA announced several initiatives to accelerate both early- and late-stage drug development as part of the Department of Health and Human Services' "Operation TrailBlazer." • A key component is a new drug pilot program designed to shorten the timeline between initial drug identification and first-in-human clinical studies.

• Opinion writers for KFF Health News address critical public health concerns, including the loss of the United States' measles-eliminated status and the safety of sunscreen. • One contributor argues that the U.S. can no longer claim to have eliminated measles due to recent outbreaks and declining vaccination rates.

• Robert F. Kennedy Jr. has announced a policy direction to reclassify 14 specific peptides, though the exact regulatory mechanics are still being finalized. • The current challenge is that none of these 14 peptides have undergone the formal FDA approval process, which requires phase 1 through 3 clinical trials and manufacturing validation.

• A new four-week clinical trial has established that daily L-tyrosine supplementation is safe and well-tolerated for healthy adults. • Researchers monitored a comprehensive range of health markers, including liver and kidney function, blood sugar, cholesterol levels, and blood amino acid concentrations.

• Early-stage research indicates that GLP-1 medications, including Ozempic, Wegovy, Zepbound, and Mounjaro, may reduce the risk of developing certain cancers. • Data shows that patients with liver, breast, colorectal, or lung cancer using these drugs were 38% to 50% less likely to progress to stage 4 disease.

• The Centers for Medicare & Medicaid Services (CMS) proposed making Medicare drug price negotiations permanent starting June 12, 2026, to lower prescription costs for Americans. • Separate health data from FAIR Health for Q1 2026 reveals that mental health is the leading telehealth diagnosis across all U.S. age groups and regions, affecting 52.1% of patients.